Patrick Harris

List of Publications by Year
in descending order

128 papers	4,539 citations	186265 28 h-index	123424 61 g-index
147 all docs	147 docs citations	147 times ranked	5918 citing authors

#	Article	IF	Citations
1	Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews, 2020, 33, .	13.6	898
2	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	7.4	538
3	The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology, 2015, 12, 570-584.	3.8	283
4	Î²-lactam and Î²-lactamase inhibitor combinations in the treatment of extended-spectrum Î²-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infectious Diseases, The, 2015, 15, 475-485.	9.1	163
5	Colistin resistance: a major breach in our last line of defence. Lancet Infectious Diseases, The, 2016, 16, 132-133.	9.1	152
6	Health Risks of Flood Disasters. Clinical Infectious Diseases, 2018, 67, 1450-1454.	5.8	108
7	Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. PLoS ONE, 2016, 11, e0153696.	2.5	104
8	Antibiotic therapy for inducible AmpC Î²-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?. International Journal of Antimicrobial Agents, 2012, 40, 297-305.	2.5	102
9	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology, 2017, 104, 11-21.	1.0	92
10	Achromobacter Infections and Treatment Options. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	82
11	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	2.5	68
12	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 296-306.	3.0	62
13	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	6.0	58
14	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	1.6	57
15	Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw459.	3.0	57
16	Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. Journal of Antimicrobial Chemotherapy, 2018, 73, 634-642.	3.0	56
17	Long-term morbidity and mortality following bloodstream infection: A systematic literature review. Journal of Infection, 2018, 77, 1-8.	3.3	53
18	Comparable outcomes for Î²-lactam/Î²-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrobial Resistance and Infection Control, 2015, 4, 14.	4.1	50

#	Article	IF	Citations
19	Antimicrobial treatment challenges in the era of carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 94, 413-425.	1.8	50
20	Discovery of mcr-1 -Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage. MSphere, 2018, 3, .	2.9	48
21	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Î²-Lactamaseâ€“Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 2021, 8, ofab387.	0.9	42
22	Central nervous system nocardiosis in Queensland. Medicine (United States), 2016, 95, e5255.	1.0	39
23	Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World Journal of Urology, 2018, 36, 323-330.	2.2	38
24	Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum-Î²-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal Unit. Journal of Clinical Microbiology, 2020, 58, .	3.9	37
25	The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis. World Journal of Urology, 2018, 36, 1007-1017.	2.2	36
26	Clinical Features That Affect Indirect-Hemagglutination-Assay Responses to Burkholderia pseudomallei. Vaccine Journal, 2009, 16, 924-930.	3.1	34
27	Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended-Spectrum Î²-Lactamase and AmpC Enzymes. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 056-073.	2.1	34
28	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei. Nature Communications, 2020, 11, 466.	12.8	34
29	Guideline of guidelines: management of recurrent urinary tract infections in women. BJU International, 2022, 130, 11-22.	2.5	32
30	Facing the challenge of multidrugâ€resistant gramâ€negative bacilli in Australia. Medical Journal of Australia, 2015, 202, 243-246.	1.7	31
31	Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
32	Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. Clinical Microbiology and Infection, 2011, 17, 1216-1222.	6.0	30
33	An update on cefepime and its future role in combination with novel Î²-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2021, 76, 550-560.	3.0	30
34	Budget impact analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia. BMJ Open, 2021, 11, e041968.	1.9	28
35	Comparative Genomics and Antimicrobial Resistance Profiling of Elizabethkingia Isolates Reveal Nosocomial Transmission and In Vitro Susceptibility to Fluoroquinolones, Tetracyclines, and Trimethoprim-Sulfamethoxazole. Journal of Clinical Microbiology, 2020, 58, .	3.9	27
36	Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a caseâ€“control study. Antimicrobial Resistance and Infection Control, 2017, 6, 14.	4.1	26

#	Article	IF	Citations
37	New Microbiological Techniques for the Diagnosis of Bacterial Infections and Sepsis in ICU Including Point of Care. Current Infectious Disease Reports, 2021, 23, 12.	3.0	26
38	Oral cephalosporin and Î²-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 2384-2393.	3.0	26
39	Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults. Lancet Infectious Diseases, The, 2014, 14, 1043.	9.1	25
40	MicroPIPE: validating an end-to-end workflow for high-quality complete bacterial genome construction. BMC Genomics, 2021, 22, 474.	2.8	25
41	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 4375-4378.	3.2	24
42	Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. Prostate Cancer and Prostatic Diseases, 2021, 24, 169-176.	3.9	24
43	Editorial Commentary: The New Acinetobacter Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble: Table 1.. Clinical Infectious Diseases, 2015, 61, 155-156.	5.8	23
44	Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. Current Opinion in Infectious Diseases, 2020, 33, 78-85.	3.1	23
45	An outbreak of scrub typhus in military personnel despite protocols for antibiotic prophylaxis: doxycycline resistance excluded by a quantitative PCR-based susceptibility assay. Microbes and Infection, 2016, 18, 406-411.	1.9	22
46	Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care. Microbial Genomics, 2021, 7, .	2.0	22
47	Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of central-line-associated bloodstream infection: a feasibility randomized controlled trial (the CLABSI) Tj ETQq1 1 0.784314 rgBT /Overlo	4.3	21
48	Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study. International Journal of Antimicrobial Agents, 2019, 54, 491-495.	2.5	20
49	Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-Î²-Lactamase- and AmpC-Producing Enterobacterales ?: a Systematic Review and Meta-analysis. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	20
50	Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread transmission of bla IMP-4 on an IncHI2 plasmid. Microbial Genomics, 2020, 6, .	2.0	19
51	Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. International Journal of Antimicrobial Agents, 2011, 37, 547-549.	2.5	18
52	Relevance of the pH probe in sleep study analysis in infants. Child: Care, Health and Development, 2004, 30, 337-344.	1.7	17
53	Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	17
54	Coxiella burnetii causing haemophagocytic syndrome: a rare complication of an unusual pathogen. Infection, 2011, 39, 579-582.	4.7	16

#	Article	IF	Citations
55	A hybrid simulation model approach to examine bacterial genome sequencing during a hospital outbreak. BMC Infectious Diseases, 2020, 20, 72.	2.9	16
56	Adhesive tape in the health care setting: another highâ€risk fomite?. Medical Journal of Australia, 2012, 196, 34-34.	1.7	15
57	Melioidosis: refining management of a tropical time bomb. Lancet, The, 2014, 383, 762-764.	13.7	15
58	Antiseptic Body Washes for Reducing the Transmission of Methicillin-Resistant Staphylococcus aureus: A Cluster Crossover Study. Open Forum Infectious Diseases, 2015, 2, ofv051.	0.9	15
59	Beyond the Core Genome: Tracking Plasmids in Outbreaks of Multidrug-resistant Bacteria. Clinical Infectious Diseases, 2021, 72, 421-422.	5.8	15
60	Herpes Zoster Meningoencephalitis: Not Only a Disease of the Immunocompromised?. Infection, 2010, 38, 73-75.	4.7	14
61	Acute Q fever in northern Queensland: variation in incidence related to rainfall and geographical location. Epidemiology and Infection, 2013, 141, 1034-1038.	2.1	14
62	Evaluation of the SpeeDx Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes. BMC Infectious Diseases, 2019, 19, 571.	2.9	14
63	Comparison of Vitek MS (MALDI-TOF) to standard routine identification methods: an advance but no panacea. Pathology, 2012, 44, 583-585.	0.6	13
64	Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2019, 6, .	0.9	13
65	Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis. JAC-Antimicrobial Resistance, 2021, 3, .	2.1	13
66	Contamination of SARS-CoV-2 RT-PCR probes at the oligonucleotide manufacturer. Pathology, 2020, 52, 814-816.	0.6	12
67	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2020, 75, 2633-2640.	3.0	12
68	Rapid detection of NDM and VIM carbapenemase encoding genes by recombinase polymerase amplification and lateral flowâ€“based detection. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2447-2453.	2.9	12
69	PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales. JAC-Antimicrobial Resistance, 2021, 3, dlab013.	2.1	12
70	Health Impact Assessment for Urban and Land-use Planning and Policy Development: Lessons from Practice. Planning Practice and Research, 2010, 25, 531-541.	1.7	11
71	Automated erythrocytapheresis for severe falciparum malaria. Internal Medicine Journal, 2011, 41, 60-63.	0.8	11
72	Modifiable risk factors for multidrugâ€resistant Gramâ€negative infection in critically ill burn patients: a systematic review and metaâ€analysis. ANZ Journal of Surgery, 2019, 89, 1256-1260.	0.7	11

#	Article	IF	Citations
73	Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (â€œMERINO-3â€): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials, 2021, 22, 301.	1.6	11
74	Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis of bloodstream infections. Heliyon, 2022, 8, e09983.	3.2	11
75	Evidence of Burkholderia pseudomallei-Specific Immunity in Patient Sera Persistently Nonreactive by the Indirect Hemagglutination Assay. Vaccine Journal, 2011, 18, 1288-1291.	3.1	10
76	Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice?. Pathology, 2015, 47, 386-388.	0.6	10
77	Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia. Value in Health, 2020, 23, 994-1002.	0.3	10
78	Diagnosis of melioidosis: the role of molecular techniques. Future Microbiology, 2021, 16, 271-288.	2.0	10
79	Morganella morganii, an Emerging Cause of Bloodstream Infections. Microbiology Spectrum, 2022, 10, e0056922.	3.0	10
80	Carriage Duration and Household Transmission of Enterobacterales Producing Extended-Spectrum Beta-Lactamase in the Community: A Systematic Review and Meta-Analysis. Microbial Drug Resistance, 2022, 28, 795-805.	2.0	10
81	Melioidosis, Singapore, 2003â€“2014. Emerging Infectious Diseases, 2017, 24, .	4.3	9
82	Molecular Epidemiology of Third-Generation-Cephalosporin-Resistant Enterobacteriaceae in Southeast Queensland, Australia. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	9
83	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
84	Laboratory Safety: Handling Burkholderia pseudomallei Isolates without a Biosafety Cabinet. Journal of Clinical Microbiology, 2021, 59, e0042421.	3.9	8
85	Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia. Microbial Genomics, 2019, 5, .	2.0	8
86	Melioidosis: Laboratory Investigations and Association with Patient Outcomes. American Journal of Tropical Medicine and Hygiene, 2022, 106, 54-59.	1.4	8
87	Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2022, 9, ofaa480.	0.9	7
88	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
89	Strengths and caveats of identifying resistance genes from whole genome sequencing data. Expert Review of Anti-Infective Therapy, 2022, 20, 533-547.	4.4	7
90	Pandemic influenza H1N1 2009 in north Queensland--risk factors for admission in a region with a large indigenous population. Communicable Diseases Intelligence Quarterly Report, 2010, 34, 102-9.	0.5	7

#	Article	IF	Citations
91	A health impact assessment on the construction phase of a major hospital redevelopment. Australian Health Review, 2008, 32, 509.	1.1	6
92	Challenges in the microbiological diagnosis and management of hVISA infections. Pathology, 2011, 43, 357-361.	0.6	6
93	Detection of carbapenemase activity in Enterobacteriaceae using LC-MS/MS in comparison with the neo-rapid CARB kit using direct visual assessment and colorimetry. Journal of Microbiological Methods, 2016, 131, 68-72.	1.6	6
94	Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infectionsâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 613.	7.4	6
95	Bacterial Profile, Multi-Drug Resistance and Seasonality Following Lower Limb Orthopaedic Surgery in Tropical and Subtropical Australian Hospitals: An Epidemiological Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 657.	2.6	6
96	Detecting antimicrobial resistance in Escherichia coli using benchtop attenuated total reflectance-Fourier transform infrared spectroscopy and machine learning. Analyst, The, 2021, 146, 6211-6219.	3.5	6
97	The epidemiology of melioidosis in Townsville, Australia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 328-335.	1.8	6
98	Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials, 2021, 22, 889.	1.6	6
99	Another Killer of the Australian Bush: A Rapidly Fatal Meningoencephalitis in a Child. Clinical Infectious Diseases, 2010, 50, 1375-1376.	5.8	5
100	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.8	5
101	Evaluating the economic effects of genomic sequencing of pathogens to prioritise hospital patients competing for isolation beds. Australian Health Review, 2021, 45, 59.	1.1	5
102	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. Clinical Microbiology and Infection, 2021, 27, 1746-1753.	6.0	5
103	In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial. Microbiology Spectrum, 2021, 9, e0022621.	3.0	5
104	Cost-effectiveness analysis of whole-genome sequencing during an outbreak of carbapenem-resistantAcinetobacter baumannii. Antimicrobial Stewardship & Healthcare Epidemiology, 2021, 1, .	0.5	5
105	Achromobacter Species: An Emerging Cause of Community-Onset Bloodstream Infections. Microorganisms, 2022, 10, 1449.	3.6	5
106	Acute Myocardial Infarction and Community-acquired Staphylococcus aureus Bloodstream Infection: An Observational Cohort Study. Clinical Infectious Diseases, 2021, 73, e2647-e2655.	5.8	4
107	OUP accepted manuscript. JAC-Antimicrobial Resistance, 2021, 3, dlab157.	2.1	4
108	Unexpected benefit of COVID-19 hospital restrictions: Reduction in patients isolating with multidrug resistant organisms after restrictions were lifted. Infection, Disease and Health, 2022, 27, 10-14.	1.1	4

#	Article	IF	Citations
109	Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial. JAC-Antimicrobial Resistance, 2022, 4, dlab192.	2.1	4
110	Bacterial identification using a SCIEX 5800 TOF/TOF MALDI research instrument and an external database. Journal of Microbiological Methods, 2019, 164, 105685.	1.6	3
111	By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract Infections?. Clinical Infectious Diseases, 2019, 69, 2057-2058.	5.8	3
112	Association between higher ambient temperature and orthopaedic infection rates: a systematic review and metaâ€analysis. ANZ Journal of Surgery, 2019, 89, 1028-1034.	0.7	3
113	CATHAI: cluster analysis tool for healthcare-associated infections. Bioinformatics Advances, 2022, 2, .	2.4	3
114	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum Î²-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy, 2022, 77, 2448-2455.	3.0	3
115	Clinical Burkholderia pseudomallei isolates from north Queensland carry diverse bimABm genes that are associated with central nervous system disease and are phylogenomically distinct from other Australian strains. PLoS Neglected Tropical Diseases, 2022, 16, e0009482.	3.0	3
116	Completing the Pictureâ€"Capturing the Resistome in Antibiotic Clinical Trials. Clinical Infectious Diseases, 2021, 72, e1122-e1129.	5.8	2
117	An update on cefepime and its future role in combination with novel Î²-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosaâ€"â€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2021, 76, 3327-3328.	3.0	2
118	The impact of COVID-19 epidemic phase and changes in mean viral loads: implications for SARS-CoV-2 testing strategies. Diagnostic Microbiology and Infectious Disease, 2021, 102, 115598.	1.8	2
119	Genomic analysis of Elizabethkingia species from aquatic environments: evidence for potential clinical transmission. Current Research in Microbial Sciences, 2021, 3, 100083.	2.3	2
120	Infectious complications following transrectal ultrasound-guided prostate biopsy: what additional diagnostic value do blood cultures provide?. Infectious Diseases, 2018, 50, 804-806.	2.8	1
121	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. Clinical Infectious Diseases, 2020, 71, 433-439.	5.8	1
122	Multiplex Microsphere PCR (mmPCR) Allows Simultaneous Gram Typing, Detection of Fungal DNA, and Antibiotic Resistance Genes. Laboratory Medicine, 2022, 53, 459-464.	1.2	1
123	Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood. Access Microbiology, 2022, 4, .	0.5	1
124	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum Î²-lactamase-producing versus non-producing Escherichia coli in a hollow-fibre infection model. International Journal of Antimicrobial Agents, 2022, , 106623.	2.5	1
125	Reply to Rezahosseini and Nielsen. Clinical Infectious Diseases, 2021, 72, e916-e916.	5.8	0
126	Discrepancy between VITEK2 and Etest aminoglycoside susceptibility testing for multidrug-resistant Acinetobacter baumannii. Pathology, 2021, 53, 805-808.	0.6	0

#	Article	IF	Citations
127	Speed and safety of mass spectrometry for identification of Burkholderia pseudomallei directly from spiked blood cultures. Journal of Medical Microbiology, 2022, 71, .	1.8	0
128	Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. Journal of Clinical Urology, 0, , 205141582210998.	0.1	0